MedTrace Logo

Central Catheters Used for Chemotherapy in Women With Breast Cancer

NCT04324346 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-03-18

No results posted yet for this study

Summary

The overall aim of this study is to evaluate two different central venous lines, PICC-lines (PICC) and subcutaneous venous access ports (SVAP) used for chemotherapy in women with breast cancer. The study will compare complications, material wear of the catheters used, patients'- and health care professionals' experiences, and costs. The study will give knowledge about which central venous access that is the most advantageous regarding adjuvant chemotherapy for women with breast cancer in the aspects of safety, quality of care, and quality of life.

Conditions

  • Catheter Related Complications

Interventions

DRUG

FEC75 (or EC90) x 6

Type of Chemotherapy

DRUG

FEC100 + Taxotere (EC90 + Taxotere) 3+3

Type of Chemotherapy

DRUG

Paclitaxel

Type of Chemotherapy

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • KTH Royal Institute of Technology

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Stockholm South General Hospital

    collaborator OTHER

  • Norwegian University of Science and Technology

    collaborator OTHER

  • Swedish Red Cross University College

    lead OTHER

Principal Investigators

  • Gunilla Björling, PhD · The Swedish Red Cross University College

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2021-02-01
Completion
2021-02-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324346 on ClinicalTrials.gov